Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study

Ravulizumab (ALXN1210), a new complement C5 inhibitor, provides immediate, complete, and sustained C5 inhibition. This phase 3, open-label study assessed the noninferiority of ravulizumab to eculizumab in complement inhibitor–naive adults with paroxysmal nocturnal hemoglobinuria (PNH). Patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Lee, Jong Wook, Sicre de Fontbrune, Flore, Wong Lee Lee, Lily, Pessoa, Viviani, Gualandro, Sandra, Füreder, Wolfgang, Ptushkin, Vadim, Rottinghaus, Scott T., Volles, Lori, Shafner, Lori, Aguzzi, Rasha, Pradhan, Rajendra, Schrezenmeier, Hubert, Hill, Anita
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367644/
https://ncbi.nlm.nih.gov/pubmed/30510080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-09-876136
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados